Olema Pharmaceuticals, Inc.

NasdaqGS OLMA

Olema Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2024

Olema Pharmaceuticals, Inc. Capital Expenditure is NA for the Trailing 12 Months (TTM) ending September 30, 2024. Capital expenditure is cash spent on acquiring or maintaining fixed assets, such as property, plants, and equipment (PP&E).

Olema Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -173.00 K, a 80.54% change year over year.
Olema Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -889.00 K, a 4.10% change year over year.
Olema Pharmaceuticals, Inc. Capital Expenditure for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -927.00 K.

Key data

Date	Capital Expenditure	Free Cash Flow	Depreciation And Amortization	Deferred Income Tax

NasdaqGS: OLMA

Olema Pharmaceuticals, Inc.

CEO	Dr. Sean P. Bohen M.D., Ph.D.
IPO Date	Nov. 19, 2020
Location	United States
Headquarters	512 2nd Street
Employees	74
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Cosmetics Drugstores & Retail Pharmacies Personal Care Pharmaceuticals

Description

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Key trends

Past 5 years